Awiqli offers eligible adults with type 2 diabetes a once-weekly alternative to daily basal insulin, reducing injections from ...

The Cystic Fibrosis Foundation organised a multidisciplinary committee to develop this Position Paper to outline current ...

GRAND RAPIDS, Mich., June 24, 2026 /PRNewswire/ -- Cirius Therapeutics, Inc., a developer of innovative therapies for people suffering from diseases caused by mitochondrial dysfunction and insulin ...

A Phase 2a study in people with type 1 diabetes (T1D) and supported by Breakthrough T1D has begun dosing. Cirius also recently announced that the Gates Foundation is providing a grant to initiate ...

Please provide your email address to receive an email when new articles are posted on . In patients with gestational diabetes, use of inhaled insulin was comparable ...

Overall, 18,556 women developed diabetes during follow-up — 20.1% with prior gestational diabetes vs 2.0% without. Of these, 655 (3.5%) developed diabetic retinopathy, and 38.1% developed hypertension ...

New evidence has emerged showing that diabetes developed during pregnancy is likely an early manifestation of type 2 diabetes, triggered by the stresses pregnancy places on the body. In the largest ...

Glooko has won FDA clearance for the EndoTool IV Cloud, a cloud-based patient-specific insulin dosing platform. The technology is a cloud-based version of EndoTool IV, which hospitals use to support ...

A new study led by Marc D. Breton, PhD, found that a University of Virginia Center for Diabetes Technology-developed algorithm – paired with a continuous glucose monitor – can help users better manage ...

For over a century, scientists have chased the dream of insulin pills, but the digestive system kept destroying the drug before it could work—forcing millions of patients to rely on daily injections.

Those who titrated their own insulin experienced more rapid glycemic control and lower risks for macrosomia than when clinicians led titration. Both approaches resulted in similar mean fasting glucose ...